ADC Therapeutics S.A.

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, ADC Therapeutics S.A. sits in the top decile of US sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count).

18 total trials 2 currently recruiting 5 completed early-phase tilt top decile by trial count

ADC Therapeutics S.A.: 18 sponsored US clinical trials, 2 recruiting.

ADC Therapeutics S.A. sponsors 18 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 5 completed. 1 of these trials are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Relapsed B-Cell Non-Hodgkin Lymphoma, with 1 trials.

Top-decile sponsor footprint

ADC Therapeutics S.A. ranks in the top decile of sponsors by registered trial count (#801 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

5 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (33.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

18 total, page 1 of 1

RECRUITING Phase 1

A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

NCT05660395
RECRUITING Phase 1

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

NCT04970901
ACTIVE NOT RECRUITING Phase 3

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT04384484
TERMINATED Phase 1

A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

NCT05389462
TERMINATED Phase 2

A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)

NCT05144009
TERMINATED Phase 2

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma

NCT04699461
COMPLETED Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors

NCT04972981
COMPLETED Phase 2

Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT04052997
TERMINATED Phase 1

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

NCT03685344
TERMINATED Phase 1

Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors

NCT03700294
TERMINATED Phase 1

Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

NCT03684694
TERMINATED Phase 1

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

NCT03621982
COMPLETED Phase 2

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT03589469
TERMINATED Phase 1

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

NCT03125200
COMPLETED Phase 1

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

NCT02669017
TERMINATED Phase 1

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

NCT02669264
TERMINATED Phase 1

Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)

NCT02588092
COMPLETED Phase 1

Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

NCT02432235

Phase Distribution

PhaseTrial count
Phase 1 13
Phase 2 4
Phase 3 1

Therapeutic Areas

Relapsed B-Cell Non-Hodgkin Lymphoma 1
Relapsed Diffuse Large B-cell Lymphoma 1
Refractory B-Cell Non-Hodgkin Lymphoma 1
Refractory Diffuse Large B-Cell Lymphoma 1
High Grade B-Cell Lymphoma 1
B-Cell Non-Hodgkin Lymphoma 1
Diffuse Large B Cell Lymphoma 1

What is open in the ADC Therapeutics S.A. pipeline

2 recruiting of 18 indexed (11% open); 5 completed (28%).

Phase mix: 1 late (III/IV) vs 17 early (I/II) (early-phase heavy).

Top condition: Relapsed B-Cell Non-Hodgkin Lymphoma (1 trial), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

ADC Therapeutics S.A.: open-pipeline peers nationwide

Peers matched on 18 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

ADC Therapeutics S.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 01020304050 0%10%20%30%40% Total trials Recruiting share ADC Therapeutics S.A.Akros PharmaAO Clinical Investigation and Publishing DocumentationAO Innovation Translation CenterBeckman CoulterAdrian VellaAIDS Malignancy ConsortiumAmylyx PharmaceuticalsAprea Therapeutics
ADC Therapeutics S.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

ADC Therapeutics S.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 18 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this ADC Therapeutics S.A. page

18 registered trials is a research-attention snapshot, not an endorsement of ADC Therapeutics S.A. or any single study.

  • 2 of ADC Therapeutics S.A.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Relapsed B-Cell Non-Hodgkin Lymphoma is the condition ADC Therapeutics S.A. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Relapsed B-Cell Non-Hodgkin Lymphoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. ADC Therapeutics S.A. pipeline card: 18 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.